Page last updated: 2024-09-03

tyrosyl-isoleucyl-glycyl-seryl-arginine and Leukemia, Pre-B-Cell

tyrosyl-isoleucyl-glycyl-seryl-arginine has been researched along with Leukemia, Pre-B-Cell in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hara, T; Ishii, E; Kinukawa, N; Matsuzaki, A; Miyazaki, S; Mohri, S; Nomizu, M; Oshima, K; Yamada, Y; Yoshida, N1

Other Studies

1 other study(ies) available for tyrosyl-isoleucyl-glycyl-seryl-arginine and Leukemia, Pre-B-Cell

ArticleYear
The laminin-derived peptide YIGSR (Tyr-Ile-Gly-Ser-Arg) inhibits human pre-B leukaemic cell growth and dissemination to organs in SCID mice.
    British journal of cancer, 1999, Volume: 80, Issue:12

    Topics: Actins; Animals; Antigens, CD19; Antineoplastic Agents; Cell Division; Humans; Laminin; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neprilysin; Oligopeptides; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Tumor Cells, Cultured

1999